HIV-1 Genotypic Resistance Testing Using Sanger and Next-Generation Sequencing in Adults with Low-Level Viremia in China

References

• World Health Organization. HIV/AIDS; 2020. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed November 7, 2022.
   Google Scholar
• Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009;151:241–251. doi:10.7326/0003-4819-151-4-200908180-00006
   PubMed Web of Science ®Google Scholar
• Zhang T, Ding H, An M, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis. 2020;201:147. doi:10.1186/s12879-020-4837-y
   Web of Science ®Google Scholar
• Li Q, Chen M, Zhao H, et al. Persistent low-level viremia is an independent risk factor for virologic failure: a retrospective cohort study in China. Infect Drug Resist. 2021;14:4529–4537. doi:10.2147/IDR.S332924
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. World Health Organization; 2016.
   Google Scholar
• Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69:2145–2152. doi:10.1093/cid/ciz129
   PubMed Web of Science ®Google Scholar
• Hermans LE, Moorhouse MM, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18:188–197. doi:10.1016/S1473-3099(17)30681-3
   PubMed Web of Science ®Google Scholar
• Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;8:1230–1238. doi:10.1093/infdis/jis104
   Web of Science ®Google Scholar
• Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis. 2001;183:539–545. doi:10.1086/318530
   PubMed Web of Science ®Google Scholar
• Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205:358–365.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204:515–520. doi:10.1093/infdis/jir353
   PubMed Web of Science ®Google Scholar
• Brown JA, Amstutz A, Nsakala BL, et al. Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. J Antimicrob Chemother. 2021;76:1294–1298. doi:10.1093/jac/dkab025
   Web of Science ®Google Scholar
• Kantor R, Delong A, Schreier L, et al. HIV second-line failure and drug resistance at high- and low-level viremia in Western Kenya. AIDS. 2018;32:2485–2496. doi:10.1097/QAD.0000000000001964
   Web of Science ®Google Scholar
• Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981–989. doi:10.1097/00002030-200404300-00005
   PubMed Web of Science ®Google Scholar
• Lu J, Ma SS, Zhang WY, et al. Changes in peripheral blood inflammatory factors (TNF-alpha and IL-6) and intestinal flora in AIDS and HIV-positive individuals. J Zhejiang Univ Sci B. 2019;20:793–802. doi:10.1631/jzus.B1900075
   PubMed Web of Science ®Google Scholar
• Bernal E, Gómez JM, Jarrín I, et al. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2018;78(3):329–337. doi:10.1097/QAI.0000000000001678
   PubMed Web of Science ®Google Scholar
• Amstutz A, Nsakala B, Vanobberghen F, et al. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in Lesotho. PLoS Med. 2020;17(9):e1003325. doi:10.1371/journal.pmed.1003325
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization; 2018.
   Google Scholar
• Vandamme A-M, Houyez F, Banhegyi D, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther. 2001;6(1):21–39. doi:10.1177/135965350100600103
   Web of Science ®Google Scholar
• Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One. 2012;7:e36673. doi:10.1371/journal.pone.0036673
   PubMed Web of Science ®Google Scholar
• Esber A, Polyak C, Kiweewa F, et al. Persistent low-level viremia predicts subsequent virologic failure: is it time to change the third 90? Clin Infect Dis. 2019;69:805–812. doi:10.1093/cid/ciy989
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Hamers RL, Julian MN, et al. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018;58:446–449.
   Google Scholar
• Johnson JA, Li JF, Wei XR, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158. doi:10.1371/journal.pmed.0050158
   PubMed Web of Science ®Google Scholar
• Balduin M, Oette M, Däumer MP, et al. prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure. J Clin Virol. 2009;45(1):34–38. doi:10.1016/j.jcv.2009.03.002
   Web of Science ®Google Scholar
• Tzou PL, Ariyaratne P, Varghese V, et al. Comparison of an in vitro diagnostic next-generation sequencing assay with sanger sequencing for HIV-1Genotypic resistance testing. J Clin Microbiol. 2018;56:e00105–e00118. doi:10.1128/JCM.00105-18
   PubMed Web of Science ®Google Scholar
• Nykoluk M, Taylor T, Enns E, et al. HyDRA web user guide; 2016. Available from: https://hydra.canada.ca/pages/about?lang=en-CA. Accessed March 20, 2022.
   Google Scholar
• Bangalee A, Hans L, Steegen K. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021;76:2659–2665. doi:10.1093/jac/dkab220
   Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1–infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1030–1037. doi:10.1086/423388
   PubMed Web of Science ®Google Scholar
• Serna AZ, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58:1165–1173. doi:10.1093/cid/ciu019
   Web of Science ®Google Scholar
• Kao SW, Liu ZH, Wu TS, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017–19. J Antimicrob Chemother. 2021;76:722–728. doi:10.1093/jac/dkaa510
   Web of Science ®Google Scholar
• Stosor V, Palella FJ, Berzins B, et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis. 2005;41(11):1671–1674. doi:10.1086/498025
   Web of Science ®Google Scholar
• Jones LE, Perelson AS. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol. 2005;67(6):1227–1251. doi:10.1016/j.bulm.2005.01.006
   Web of Science ®Google Scholar
• Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000;181(2):522–531. doi:10.1086/315260
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Swenson LC, Watson B, et al. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infect. 2016;22(12):1004–e9.
   Web of Science ®Google Scholar
• Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105–113. doi:10.1097/00126334-200110010-00001
   PubMed Web of Science ®Google Scholar
• Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56:5998–6000. doi:10.1128/AAC.01217-12
   PubMed Web of Science ®Google Scholar
• Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195–200. doi:10.1016/j.jinf.2004.11.010
   PubMed Web of Science ®Google Scholar
• Yu F, Li Q, Wang L, et al. Drug resistance to HIV-1 integrase inhibitors among treatment-naive patients in Beijing, China. Pharmgenomics Pers Med. 2022;15:195–203. doi:10.2147/PGPM.S345797
   PubMed Web of Science ®Google Scholar
• Yuan HB, Liu ZQ, Wu XF, et al. Prevalence of transmitted HIV-1 drug resistance among treatment-naïve individuals in China, 2000–2016. Arch Virol. 2021;166:2451–2460. doi:10.1007/s00705-021-05140-9
   Web of Science ®Google Scholar
• Chen NY, Kao SW, Liu ZH, et al. Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection. Int J Infect Dis. 2020;93:182–191. doi:10.1016/j.ijid.2020.02.004
   Web of Science ®Google Scholar
• Li M, Liang S, Zhou C, et al. HIV drug resistance mutations detection by next-generation sequencing during antiretroviral therapy interruption in China. Pathogens. 2021;10:264. doi:10.3390/pathogens10030264
   PubMed Web of Science ®Google Scholar
• Geretti AM, Fox ZV, Booth CL, et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;52:569–573. doi:10.1097/QAI.0b013e3181ba11e8
   Web of Science ®Google Scholar
• Kyeyune F, Gibson RM, Nankya I, et al. Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure. Antimicrob Agents Chemother. 2016;60:3380–3397. doi:10.1128/AAC.00038-16
   Web of Science ®Google Scholar
• Mbunkah HA, Bertagnolio S, Hamers RL, et al. Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: a systematic review of detection methods, prevalence, and clinical impact. J Infect Dis. 2020;221:1584–1597. doi:10.1093/infdis/jiz650
   PubMed Web of Science ®Google Scholar